Search

Displaying results 4841 - 4850 of 7687 in total
  1. Drug

    ECT-001 expanded cord blood

    go.drugbank.com/drugs/DB21745
    Investigational

    [L52013] It is being investigated in hematopoietic cell transplantation as ECT-001 expanded cord blood can demonstrate enhanced stem cell proliferation and engraftment compared to untreated UBCs.

  2. Drug

    Disitamab vedotin

    go.drugbank.com/drugs/DB17208
    Investigational

    Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.[A254721]

  3. Drug

    Ixmyelocel-T

    go.drugbank.com/drugs/DB17601
    Investigational

    Ixmyelocel-T is an expanded, autologous multicellular therapy cultured from bone-marrow mononuclear cells. Developed by Vericel Corporation, it is being investigated for cardiomyopathy.

  4. Drug

    ADVM-062

    go.drugbank.com/drugs/DB18341
    Experimental

    ADVM-062 is an adeno-associated virus vector carrying complementary deoxyribonucleic acid encoding the human long-wave-sensitive opsin 1 (AAV.7m8-L-opsin)

  5. Drug

    Glembatumumab vedotin

    go.drugbank.com/drugs/DB05996
    Investigational

    A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.

  6. Drug

    Anisomycin

    go.drugbank.com/drugs/DB07374
    Experimental

    Anisomycin (sometimes known as flagecidin), is an antibiotic retrieved from the bacteria _Streptomyces griseolus_. This drug acts to inhibit bacterial protein and DNA synthesis.

  7. Drug

    Pentanal

    go.drugbank.com/drugs/DB01919
    Experimental

    Pentanal is an aldehyde that is liquid at room temperature. It is occasionally a minor ingredient in some cosmetic products like perfumes.[L53886,L53891]

  8. Drug

    ENTR-601-44

    go.drugbank.com/drugs/DB17836
    Investigational

    ENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]

  9. Drug

    GB-13

    go.drugbank.com/drugs/DB18387
    Experimental

    GB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A.

  10. Drug

    PAS-004

    go.drugbank.com/drugs/DB18611
    Investigational

    PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.